Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3036200 | 0.87 | KDM4E (0.56) | DHODHKDM4EALDH1A1POLBHPGD | |
| SCHEMBL641481 | 0.80 | KDM4E (0.62) | DHODHKDM4EALDH1A1POLBHPGD | |
| SCHEMBL6584881 | 0.79 | KDM4E (0.56) | KDM4EALDH1A1POLBHPGDHSD17B10 | |
| SCHEMBL7533914 | 0.78 | CYP2D6 (0.55) | DHODHKDM4EALDH1A1POLBHPGD | |
| Hydrochloric Acid SCHEMBL7531424 | 0.78 | KDM4E (0.54) | KDM4EALDH1A1POLBHPGDHSD17B10 | |
| SCHEMBL22969068 | 0.73 | KDM4E (0.53) | DHODHKDM4EALDH1A1POLBHPGD | |
| SCHEMBL923917 | 0.72 | MMP13 (0.55) | RAB9ASMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL3036378 | 0.72 | POLB (0.55) | DHODHKDM4EALDH1A1POLBHPGD | |
| SCHEMBL13985404 | 0.71 | DHODH (0.58) | DHODHKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL7702486 | 0.71 | ALOX15 (0.57) | DHODHKDM4EALDH1A1POLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9575062-B2 | Zwitterion-containing acridinium compounds | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20140295575-A1 | ZWITTERION-CONTAINING ACRIDINIUM COMPOUNDS | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2014-10-02 | — | — | US | disclosed |
| EP-1403254-B1 | Novel applications of acridinium compounds and derivatives in homogeneous assays | SIEMENS HEALTHCARE DIAGNOSTICS (US) | 2014-09-17 | — | — | EP | disclosed |
| US-8778624-B2 | Zwitterion-containing acridinium compounds | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20120225497-A1 | ZWITTERION-CONTAINING ACRIDINIUM COMPOUNDS | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-7875467-B2 | Chemiluminescence; quantitative analysis of macromolecules; complexing sample to acridinium compound, labels for improving sensitivity of immunoassays, 2',6'-dimethyl-4'-N-succinimidyloxycaproyl-amidocarbonylphenyl-N10-2,7-tris[O-methoxyhexa(ethylene) glycol-sulfonamidylpropyl]-acridinium-9-carboxylate | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20090029349-A1 | Novel Applications of Acridinium Compounds and Derivatives in Homogeneous Assays | SIEMENS MEDICAL SOLUTIONS DIAGNOSTICS (US) | 2009-01-29 | — | — | US | disclosed |
| US-20080305557-A1 | Novel Applications of Acridinium Compounds and Derivatives in Homogeneous Assays | SIEMENS MEDICAL SOLUTIONS DIAGNOSTICS (US) | 2008-12-11 | — | — | US | disclosed |
| US-7319041-B2 | Applications of acridinium compounds and derivatives in homogeneous assays | SIEMENS MEDICAL SOLUTIONS DIAGNOSTIC (US) | 2008-01-15 | — | — | US | disclosed |
| US-20040063147-A1 | Novel applications of acridinium compounds and derivatives in homogeneous assays | BAYER CORPORATION | 2004-04-01 | — | — | US | disclosed |
| EP-1403254-A1 | Novel applications of acridinium compounds and derivatives in homogeneous assays | Bayer Healthcare, LLC (US) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063147-A1 | Novel applications of acridinium compounds and derivatives in homogeneous assays | ACR, SSB, NASP | DHODH 4196/4885KDM4E 4637/4885ALDH1A1 2032/4885 |
| US-20120225497-A1 | ZWITTERION-CONTAINING ACRIDINIUM COMPOUNDS | ACR, SSB, FCGR3B | DHODH 3794/4885KDM4E 3916/4885ALDH1A1 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.